Literature DB >> 23529385

Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer.

James L Murray1, Patricia Thompson, Suk Young Yoo, Kim-Anh Do, Mala Pande, Renke Zhou, Yanhong Liu, Aysegul A Sahin, Melissa L Bondy, Abenaa M Brewster.   

Abstract

To examine the role of germline genetic variations in inflammatory pathways as modifiers of time to recurrence (TTR) in patients with early stage breast cancer (BC), DNA from 997 early stage BC patients was genotyped for 53 tagging single nucleotide polymorphisms (SNPs) in 12 genes involved in inflammation. SNPs were analyzed separately for Caucasians versus African-Americans and Hispanics. Cox proportional hazards models were used to evaluate the association between SNPs in the inflammatory genes and TTR, adjusted for clinical and pathologic covariates. In univariable analyses of Caucasian women, the homozygous genotype of 12 SNPs, including 6 NFKB1 SNPs, 4 IL4 SNPs, and 2 IL13 SNPs, were significantly associated with a decrease in TTR compared with the heterozygous and/or corresponding homozygous genotype (P < 0.05). The significant NFKB1 and IL4 SNPs were in an area of high linkage disequilibrium (D' > 0.8). After adjusting for stage, age, and treatment, carriage of the homozygous genotypes for NFKB1 rs230532 and IL13rs1800925 were independently associated with a shorter TTR (P = 0.001 and P = 0.034, respectively). In African-American and Hispanic patients, expression of NFKB1 rs3774932, TNFrs1799964, and IL4rs3024543 SNPs were associated with a shorter TTR in univariable model. Only NFKB1 rs3774932 (P = 0.02) and IL4Rrs3024543 (P = 0.03) had independent prognostic value in the multivariable model These data support the existence of host genetic susceptibility as a component in recurrence risk mediated by pro-inflammatory and immune factors, and suggest the potential for drugs which modify immune responses and inflammatory genes to improve prognosis in early stage BC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529385      PMCID: PMC3746974          DOI: 10.1007/s10549-013-2445-x

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  46 in total

1.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

2.  The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells.

Authors:  Rebecca B Riggins; Alan Zwart; Ruchi Nehra; Robert Clarke
Journal:  Mol Cancer Ther       Date:  2005-01       Impact factor: 6.261

3.  Influence of hypoxia and glucose deprivation on tumour necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor expression in human cultured monocytes.

Authors:  E Guida; A Stewart
Journal:  Cell Physiol Biochem       Date:  1998

4.  Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules.

Authors:  R A Kurt; W J Urba; J W Smith; D D Schoof
Journal:  Int J Cancer       Date:  1998-09-25       Impact factor: 7.396

5.  Relationship between epidemiologic risk factors and breast cancer recurrence.

Authors:  Abenaa M Brewster; Kim-Anh Do; Patricia A Thompson; Karin M Hahn; Aysegul A Sahin; Yumei Cao; Maureen M Stewart; James L Murray; Gabriel N Hortobagyi; Melissa L Bondy
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544

6.  Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development.

Authors:  Caroline Aspord; Alexander Pedroza-Gonzalez; Mike Gallegos; Sasha Tindle; Elizabeth C Burton; Dan Su; Florentina Marches; Jacques Banchereau; A Karolina Palucka
Journal:  J Exp Med       Date:  2007-04-16       Impact factor: 14.307

7.  Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review.

Authors:  S P Balasubramanian; I A F Azmy; S E Higham; A G Wilson; S S Cross; A Cox; N J Brown; M W Reed
Journal:  BMC Cancer       Date:  2006-07-14       Impact factor: 4.430

Review 8.  Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression.

Authors:  David G DeNardo; Lisa M Coussens
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

9.  Allowing for mandatory covariates in boosting estimation of sparse high-dimensional survival models.

Authors:  Harald Binder; Martin Schumacher
Journal:  BMC Bioinformatics       Date:  2008-01-10       Impact factor: 3.169

10.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.

Authors:  Andrew E Teschendorff; Ahmad Miremadi; Sarah E Pinder; Ian O Ellis; Carlos Caldas
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  8 in total

1.  Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: the Breast Cancer Health Disparities Study.

Authors:  Martha L Slattery; Jennifer S Herrick; Gabriella Torres-Mejia; Esther M John; Anna R Giuliano; Lisa M Hines; Mariana C Stern; Kathy B Baumgartner; Angela P Presson; Roger K Wolff
Journal:  Carcinogenesis       Date:  2014-03-26       Impact factor: 4.944

2.  Association of Genetic Variants in NF-kB with Susceptibility to Breast Cancer: a Case Control Study.

Authors:  Rabeb M Ghali; Sana Mahjoub; Sonia Zaied; Hanen Bhiri; Wael Bahia; Touhami Mahjoub; Wassim Y Almawi
Journal:  Pathol Oncol Res       Date:  2018-07-19       Impact factor: 3.201

3.  US breast cancer mortality trends in young women according to race.

Authors:  Foluso O Ademuyiwa; Feng Gao; Lin Hao; Daniel Morgensztern; Rebecca L Aft; Cynthia X Ma; Matthew J Ellis
Journal:  Cancer       Date:  2014-12-05       Impact factor: 6.860

4.  The prognostic value of IL10 and TNF alpha functional polymorphisms in premenopausal early-stage breast cancer patients.

Authors:  Erika Korobeinikova; Dana Myrzaliyeva; Rasa Ugenskiene; Danguole Raulinaityte; Jurgita Gedminaite; Kastytis Smigelskas; Elona Juozaityte
Journal:  BMC Genet       Date:  2015-06-26       Impact factor: 2.797

5.  Identification of Genetic and Epigenetic Variants Associated with Breast Cancer Prognosis by Integrative Bioinformatics Analysis.

Authors:  Arunima Shilpi; Yingtao Bi; Segun Jung; Samir K Patra; Ramana V Davuluri
Journal:  Cancer Inform       Date:  2017-01-09

Review 6.  Immune Responses and Risk of Triple-negative Breast Cancer: Implications for Higher Rates among African American Women.

Authors:  Joshua W Ogony; Derek C Radisky; Kathryn J Ruddy; Steven Goodison; Daniel P Wickland; Kathleen M Egan; Keith L Knutson; Yan W Asmann; Mark E Sherman
Journal:  Cancer Prev Res (Phila)       Date:  2020-08-04

7.  SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival.

Authors:  Maral Jamshidi; Rainer Fagerholm; Sofia Khan; Kristiina Aittomäki; Kamila Czene; Hatef Darabi; Jingmei Li; Irene L Andrulis; Jenny Chang-Claude; Peter Devilee; Peter A Fasching; Kyriaki Michailidou; Manjeet K Bolla; Joe Dennis; Qin Wang; Qi Guo; Valerie Rhenius; Sten Cornelissen; Anja Rudolph; Julia A Knight; Christian R Loehberg; Barbara Burwinkel; Frederik Marme; John L Hopper; Melissa C Southey; Stig E Bojesen; Henrik Flyger; Hermann Brenner; Bernd Holleczek; Sara Margolin; Arto Mannermaa; Veli-Matti Kosma; Laurien Van Dyck; Ines Nevelsteen; Fergus J Couch; Janet E Olson; Graham G Giles; Catriona McLean; Christopher A Haiman; Brian E Henderson; Robert Winqvist; Katri Pylkäs; Rob A E M Tollenaar; Montserrat García-Closas; Jonine Figueroa; Maartje J Hooning; John W M Martens; Angela Cox; Simon S Cross; Jacques Simard; Alison M Dunning; Douglas F Easton; Paul D P Pharoah; Per Hall; Carl Blomqvist; Marjanka K Schmidt; Heli Nevanlinna
Journal:  Oncotarget       Date:  2015-11-10

8.  Genetic variants in genes related to inflammation, apoptosis and autophagy in breast cancer risk.

Authors:  Johanna M Schuetz; Anne Grundy; Derrick G Lee; Agnes S Lai; Lindsay C Kobayashi; Harriet Richardson; Jirong Long; Wei Zheng; Kristan J Aronson; John J Spinelli; Angela R Brooks-Wilson
Journal:  PLoS One       Date:  2019-01-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.